Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion

ConclusionsSystemic exposure to dFdCTP was higher after BAI than IV in two out of three patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research